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Abstract 
We describe the development of a model describing 
the  use  of  patient  information  to  improve  patient 
recruitment  in  clinical  trials.  This  model,  named 
ePaIRing  (electronic  Participant  Identification  and 
Recruitment  Model)  describes  variations  in  how 
information  flows  between  stakeholders,  and  how 
personal  health  records  can  specifically  facilitate 
patient recruitment. 
Introduction 
Breakthroughs in the basic biomedical sciences have 
provided  an  unprecedented  supply  of  information 
with the potential to improve human health. Clinical 
trials research is an important step for translating such 
information into knowledge that will benefit clinical 
practice  and  human  health.    In recent years, many, 
including the United States Congress, have expressed 
their concern about the lack of continuity between the 
promise  of  basic science and the delivery of better 
health
[1].  According  to  recent  data,  a  clinical  trial 
averages $124 million and takes more than a decade 
to  complete  per  drug  candidate
[2],  with  half  of  this 
time  spent  on  patient,  site,  and  investigator 
recruitment
[3].  In  a  recent  large,  multi-center 
randomized  controlled  trial,  about  86.8  staff  hours 
and  more  than  $1000  was  spent  to  recruit  each 
randomized  participant[4].    Presently,  eighty-six 
percent  of  all  clinical  trials  are  delayed  in  patient 
recruitment for 1-6 months and 13% are delayed by 
more than 6 months
[5, 6].  
The  clinical  research  environment  is  increasingly 
burdened  with  rising  costs,  slowly  obtained  results, 
and  declining  participation  from  both  investigators 
and subjects.  The number of subjects needed for an 
FDA-registry trial has doubled in the past decade, but 
only 7% of eligible subjects and 3% of eligible cancer 
patients enroll in clinical trials annually
[7].  Although 
barriers  to  clinical  trial  enrollment  include  patient 
factors
[8] and physician factors
[9], a major deterrent to 
enrollment  is  the  challenge  of  recruiting  eligible 
patients,  which  has  traditionally  been  a  labor-
intensive manual procedure.  Studies have shown that 
up  to  60%  of  the  eligible  patients  can  miss  being 
identified
[10,  11],  which  means  these  patients  miss 
valuable treatment opportunities. Therefore, there is 
an  urgent  need  for  improving  the  accuracy  and 
efficiency  in  patient  eligibility  identification  for 
clinical trials.  
The  broad  deployment  of  EHR  systems  has  made 
enormous  amounts  of  information  about  potential 
clinical  research  participants  available  in  EHR 
systems. In addition, within the past year, Microsoft 
and Google both released personalized health records 
(PHR) software. Very soon, patients will be able to 
enter their health information electronically and share 
such  information  online.  Mandl  and  Kohane 
commented this phenomenon as “Tectonic Shifts in 
the Health Information Economy.”
[12]  
The advent of PHR and the broad adoption of EHR 
has  created  unprecedented  opportunities  for 
automating  clinical  trials  recruitment,  but  also  put 
forth  significant  regulatory  and  privacy-related 
challenges for informatics researchers. “How can we 
leverage the information in PHR and EHR to improve 
automated clinical trial recruitment without violating 
patient  privacy”  is  center  to  the  discussion  of  this 
paper.    At  the  end  of  the  discussion,  this  paper 
proposes  a  new  informatics  model  that  integrates 
EHR  and  PHR  for  automated  clinical  trials 
recruitment.  
Model Development 
We  created  our  model  by  following  an  approach 
adapted  from  grounded  theory  analysis,  developing 
the  model  inductively  from  existing  data  and 
knowledge.  Grounded theory is a qualitative method 
that  starts  by  collecting  data,  and  then  iteratively 
interpreting that data by coding key points, grouping 
data  and  points  by  concepts,  forming  categories 
around the concepts, and eventually creating a theory 
or  model  that  explains  the  data.  It  is  a  process 
whereby  researchers  can  gather  data  and  then 
systematically  generate  and  develop  theory  directly 
from the data.  We diverged from grounded theory in 
the data collection, because we generated it directly 
from  experts,  but  the  analysis  followed  the  same 
qualitative iterations. The analysis was performed by 
two of the authors (AW, CW), who were experienced 
with various aspects of informatics and clinical trial 
recruitment. 
For  data  generation,  we  first  identified  various 
stakeholders who might be relevant to a clinical trial 
recruitment  system.    These  stakeholders  were  the 
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principal  investigator,  the  patient,  the  physician 
treating  the  patient,  the  study  coordinator,  and  the 
study sponsor.  For each stakeholder, we documented 
the information resources that were available to the 
stakeholder, and the information resources that were 
needed by the stakeholder.  We then identified how 
those  needs  were  currently  being  met,  or  might  be 
met in the future.   
For  the  second  and  third  stages  of  the  model 
development,  we  coded  key  points  around  the 
stakeholder resources or needs, eventually classifying 
each resource or need and grouping into themes.  This 
resulted in 7 different themes around the information 
needed to flow among the stakeholders.   These were 
patient  clinical  information,  patient  consent,  study 
inclusion  criteria,  incentives  for  participation, 
identification  of  physicians  with  relevant  patient 
populations,  communication  with  patients,  and 
whether a patient fits the study inclusion criteria.  The 
first iteration of coding and grouping was focused on 
completeness.  The  second  iteration  was  focused on 
significance.  To this end, we then reviewed both the 
stakeholders  and  themes,  and  identified  those  that 
were most significant to the recruitment process. This 
resulted  in  3  significant  actors  in  recruitment 
(principal investigators, physicians, and patients), and 
2 key themes among those actors (criteria matching, 
and  patient  consent).    Coordinators  and  sponsors 
were  identified  as  important  stakeholders,  but  not 
direct  actors  in  the  recruitment  process.  Criteria 
matching was defined as the information needed in 
the  process  of  identifying  patients  as  potential 
subjects in the study, and patient consent was defined 
as  information  indicating  patient  agreement  to 
participate in the recruitment and study process.   
Once the categories and themes were identified, our 
final  stage  in  model  development  was  to  analyze 
relationships  among  the  categories  and  themes,  to 
eventually  identify  theories.    We  focused  on  the  3 
actors in recruitment, and identified the information 
flow of the 2 significant themes among these actors.  
We also coded and classified the methods where the 
information needs were currently or could be met, as 
either  through  paper-based  systems  or  electronic 
systems.    The electronic systems were identified in 
terms of the main actors use of the systems, and were 
then classified as either electronic health records or 
personal health records. 
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Figure 1: Information flow among actors in the recruitment process. Two types of information– criteria matching 
(red) and patient consent (blue) flow between the principal investigator (PI), patient (Pt), and physician (MD) in the 
process.  In the traditional model, only the investigator and patient are involved.  In the brokered model, the 
physician is the source of criteria matching information, and the broker for the consent. In the information-enabled 
model, the patient is the source of consent, and the personal health record, controlled by the patient, acts as a 
broker of the criteria matching information coming from the physician.   
Model Description 
We identified the main flow of consent information 
going  between  the  principal  investigator  and  the 
patient,  with  the  physician  serving  as  a  broker 
between the other two actors. The criteria matching 
information  also  flowed  between  the  principal 
investigator  and  the  patient,  but  was  less  complete 
when it did so;  the more complete data originated 
with the physician and the medical record.  This led 
to a model containing three variations, or levels, of 
information  flow  of  consent  and  criteria  matching 
between  the  actors  in  patient  recruitment.    These 
levels  are  traditional,  brokered,  and  information-
enabled (Figure 1).  In the traditional level, consent 
and  criteria  matching  flow  directly  between  the 
principal investigator and the patient. In the brokered 
level,  the  physician  identifies  patients  by  matching 
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their clinical information with the selection criteria, 
and then requests patient consent. In the information-
enabled  model,  clinical  information  flows  from  the 
physician to the patient, where it can be matched with 
selection criteria, and patient consent is given directly 
by the patient to the principal investigator. 
The  traditional  level  is  frequently  implemented  as 
recruitment posters, where principal investigators can 
publish  matching  criteria  in  advertisements,  and 
patients can individually match their own data, and 
give  consent  and  volunteer  participation  when  they 
consider  themselves  eligible.    This  model  has  two 
main  limitations:  the  matching  criteria  must  be 
understood by the patient, and the recruitment must 
be  initiated  by  the  patient.    While  most  traditional 
implementations use paper-based methods, some use 
electronic  tools  to  facilitate  recruitment.    For 
example, BreastCancerTrials.org allows a patient to 
enter clinical information, and match multiple clinical 
trials at once, leading to potentially more visibility of 
trials, at least to those patients who use the system. 
At  the  brokered  level,  the  physician  performs  the 
matching of clinical data to the patient, at the request 
of the principal investigator.  The physician also asks 
the patient for consent to participate.  The physician 
is the provider of the clinical data, and the broker for 
patient  consent.  This is potentially a more efficient 
mechanism, because the physician is a single point of 
access to multiple patients.  In addition, the physician 
may  have  more  precise  matching  information  with 
clinical information in the medical record, allowing 
for  more  complicated  or  more  sensitive  matching 
criteria. Another advantage to the brokered level is 
that  patient  consent  may  be  more  likely  than  other 
mechanisms,  since  physician  recommendations  for 
participation  in  clinical  trials  is  known  to  be  a 
significant factor influencing patient decision making.  
The  disadvantage  of  this  model  is  that  patient 
recruitment  is  dependent  on  the  physician 
participating as a broker in trial recruitment. Like the 
traditional level, the brokered level also benefits from 
electronic  data  by  improving  the  efficiency  of 
implementation.  For example, electronic data can be 
queried for matching criteria, and then alerts can be 
delivered  to  the  physician  during  convenient 
opportunities for patient recruitment. 
At the information-enabled level, the data that would 
be  queried  in  the  brokered  level  are  moved  to  the 
personal  health  record  (PHR),  where  they  can  be 
queried  with  consent  of  the  patient.    Patients  who 
have elected to be notified of potential trials can have 
data  queried  for matching criteria.  These data can 
include both patient-entered data, and data collected 
in electronic medical records and then transferred to 
PHRs.  The benefits of the information-enabled level 
is  that  the  data  are  as  complete  as  the  data  in  the 
brokered level, but consent is then obtained directly 
from the patient as in the traditional level.  The main 
disadvantage is that it depends on broad acceptance 
and use of PHRs, far above current use.  In addition, 
the  enabled  level  may  not  be  as  efficient  as  the 
brokered  level,  because  patients  are  not  being 
recommended directly by their physicians.  However, 
other  factors  that  influence  participation,  such  as 
timelines for recruitment may be better facilitated at 
the enabled level. 
The actual implementation of While all three levels 
make use of electronic data to improve the efficiency 
of  an  otherwise  paper-based  process,  the  brokered 
and enabled levels also can use data either passively 
and  actively.    For  example,  at  the  brokered  level, 
passive use of data would include querying the data in 
the EMR to identify a set of patients who could be 
recruited,  while  active  use  would  be  alerting 
physicians to recommend participation during a visit.  
At  the  enabled  level,  passive  use  of  data  would 
include  querying  to  identify  available  trials  that 
matched an individual patient’s data, while active use 
would alert patients directly of trials they matched, 
and request participation directly.  Figure 2 indicates 
how this would work in implementation. 
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Discussion 
Our  model  of  patient  recruitment  identifies  two 
important requirements: the patient must be matched 
to  the  appropriate  trial,  and  the  patient  must  give 
consent  to  be  recruited.  While  the  patient  and 
principal  investigator  are  required  stakeholders,  we 
have  also  identified  the  physician  as  an  important 
stakeholder,  who  likely  has  the  most  complete  and 
detailed information available for matching patients 
to clinical trials, and can broker between the patient 
and  principal  investigator  in  obtaining  consent  for 
participation.  Based on the relationships between the 
requirements  and  the  significant  stakeholders,  we 
identified  three  variations  or  levels  of  interaction 
among  the  stakeholders:  traditional,  brokered  and 
information-enabled.  At each level, the requirements 
are facilitated by the use of electronic data.   
Our  model  is  significant  because  it  identifies  how 
personal health records specifically can be used, and 
how the implementation of the model changes with 
PHR  use.    Even  the  more  advanced  models  of 
recruitment using electronic health records have only 
addressed mechanisms for automated identification of 
potential  subjects  through  the  electronic  medical 
records of physicians [13].  In addition, our model 
informs how data can be passive, by allowing access, 
or  active,  by  evoking  alerts.  Finally,  the  model 
describes information flow independent of the format 
of that data (paper-based or electronic), and identifies 
the specific benefits of electronic data. 
There  are  significant  issues  that  still  need  to  be 
resolved  with  this  model,  relating  to  legal,  privacy 
and institutional review board requirements.  Current 
use has allowed the physician to serve as a broker for 
consent, but also to access the medical record data 
directly.    This  is  possible  because  the  physician 
already has access o the data, and therefore it does 
not expand the scope of who looks at the data.  In the 
information enabled model, consent is obtained from 
the patient for participation, but it is not clear what 
level  of  consent  is  needed  to  identify  potential 
matches to studies.  Since the access to the data is by 
a  machine,  rather  than  an  individual,  such  direct 
access  to  data  may  be  allowed.    In  this  way,  the 
matching would follow a policy similar to the privacy 
policy in use at Google Mail [14].  The acceptance of 
Google  and  Gmail  may  indicate  the  potential  of 
computing  matches  rather  than  querying  directly.  
Further  model  development  and  research  may  be 
necessary  to  clearly  specify  the  legal  and  privacy 
issues. 
While  this  model  was  successful  at  identifying  the 
potential use of PHRs in recruitment, it is speculative, 
and  its  realization  depends  directly on the maturity 
and use of PHRs in the future.  Currently, the use of 
PHRs is still too low to test the utility of the model. 
However, the model does have content validity.  In 
addition,  the  value  of  the  model  is  that  it  is 
speculative,  that  it  predicts  what  the  clinical  trials 
recruitment approach may become after widespread 
adoption  of  PHRs.  The  model  is  also  useful  in 
identifying  requirements  of  PHRs,  and  in  directing 
PHR architecture, while PHR models are still being 
debated  [15].    Finally,  the  model  informs 
considerations  for  consent  law  based  on  PHRs and 
patient recruitment. 
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Figure 2: 1) A researcher submits a study protocol into a clinical trials registry.  Then, the 
researcher gets a study population size returned via the match engine. 2) Patients enter their PHR 
and the match engine provides a list of the clinical studies they are eligible for. 
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There  are  multiple  limitations  to  the  model 
development  we  have  employed.  First,  our  data 
source  from  which  we  derived  stakeholders  and 
significant  requirements  was  limited,  based  on  the 
experience of two experts in recruitment.  While we 
have  been  involved  in  multiple  levels  of  patient 
recruitment for clinical trials, other experts may have 
identified  different  stakeholders,  that  if  considered, 
would be seen as more important than those included 
in  our  model.  We  developed  the  model  using  a 
methodology adapted from grounded theory analysis.  
Typically,  grounded  theory  is  based  on  field  work 
data, rather than expert-generated topics. In addition, 
while our analysis did proceed somewhat iteratively, 
it is not clear that we specifically reached a point of 
theoretical saturation. However, it was clear that we 
were not biased in our analysis approach and in our 
results, as we were surprised by the outcome of the 
process. Finally, we were limited by the size of the 
study, and did not perform other studies to triangulate 
our findings.   
Conclusion 
We  developed  a  model  that  describes  variations  of 
how  stakeholders  meet  requirements  for  patient 
recruitment to clinical trials. This model was based on 
a  qualitative  development  process.    The  model 
describes  necessary  information  flow  between 
investigators, patients and physicians, and specifically 
predicts how the flow of information is affected by 
the projected use of personal health records. 
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